<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Public Health</journal-id><journal-id journal-id-type="iso-abbrev">J Infect Public Health</journal-id><journal-title-group><journal-title>Journal of Infection and Public Health</journal-title></journal-title-group><issn pub-type="ppub">1876-0341</issn><issn pub-type="epub">1876-035X</issn><publisher><publisher-name>The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S1876-0341(20)30432-9</article-id><article-id pub-id-type="doi">10.1016/j.jiph.2020.03.019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Coronavirus disease 2019 (COVID-19): A literature review</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Harapan</surname><given-names>Harapan</given-names></name><email>harapan@unsyiah.ac.id</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Itoh</surname><given-names>Naoya</given-names></name><email>itohnaoya0925@ybb.ne.jp</email><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Yufika</surname><given-names>Amanda</given-names></name><email>amandayufika@gmail.com</email><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Winardi</surname><given-names>Wira</given-names></name><email>wira.winardi@unsyiah.ac.id</email><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Keam</surname><given-names>Synat</given-names></name><email>synat.keam@research.uwa.edu.au</email><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="aut0030"><name><surname>Te</surname><given-names>Haypheng</given-names></name><email>hayphengte@gmail.com</email><xref rid="aff0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="aut0035"><name><surname>Megawati</surname><given-names>Dewi</given-names></name><email>amegawati@ucdavis.edu</email><xref rid="aff0045" ref-type="aff">i</xref><xref rid="aff0050" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="aut0040"><name><surname>Hayati</surname><given-names>Zinatul</given-names></name><email>hayatikarmil@unsyiah.ac.id</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="aff0055" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="aut0045"><name><surname>Wagner</surname><given-names>Abram L.</given-names></name><email>awag@umich.edu</email><xref rid="aff0060" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="aut0050"><name><surname>Mudatsir</surname><given-names>Mudatsir</given-names></name><email>mudatsir@unsyiah.ac.id</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref></contrib><aff id="aff0005"><label>a</label>Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0010"><label>b</label>Tropical Disease Centre, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0015"><label>c</label>Department of Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0020"><label>d</label>Division of Infectious Diseases, AichiCancer Center Hospital, Chikusa-ku Nagoya, Japan</aff><aff id="aff0025"><label>e</label>Department of Family Medicine, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0030"><label>f</label>Department of Pulmonology and Respiratory Medicine, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0035"><label>g</label>School of Medicine, The University of Western Australia, Perth, Australia</aff><aff id="aff0040"><label>h</label>Siem Reap Provincial Health Department, Ministry of Health, Siem Reap, Cambodia</aff><aff id="aff0045"><label>i</label>Department of Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Warmadewa University, Denpasar, Indonesia</aff><aff id="aff0050"><label>j</label>Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA</aff><aff id="aff0055"><label>k</label>Department of Clinical Microbiology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</aff><aff id="aff0060"><label>l</label>Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, MI 48109, USA</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Jl. T. Tanoeh Abe, Darussalam, Banda Aceh 23111, Indonesia. <email>harapan@unsyiah.ac.id</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>8</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>5</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>8</day><month>4</month><year>2020</year></pub-date><volume>13</volume><issue>5</issue><fpage>667</fpage><lpage>673</lpage><history><date date-type="received"><day>6</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Authors</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0005"><p>In early December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), occurred in Wuhan City, Hubei Province, China. On January 30, 2020 the World Health Organization declared the outbreak as a Public Health Emergency of International Concern. As of February 14, 2020, 49,053 laboratory-confirmed and 1,381 deaths have been reported globally. Perceived risk of acquiring disease has led many governments to institute a variety of control measures. We conducted a literature review of publicly available information to summarize knowledge about the pathogen and the current epidemic. In this literature review, the causative agent, pathogenesis and immune responses, epidemiology, diagnosis, treatment and management of the disease, control and preventions strategies are all reviewed.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>2019-nCoV</kwd><kwd>COVID-19</kwd><kwd>Outbreak</kwd><kwd>SARS-CoV-2</kwd><kwd>Novel coronavirus</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>Background</title><p id="par0005">On December 31, 2019, the China Health Authority alerted the World Health Organization (WHO) to several cases of pneumonia of unknown aetiology in Wuhan City in Hubei Province in central China. The cases had been reported since December 8, 2019, and many patients worked at or lived around the local Huanan Seafood Wholesale Market although other early cases had no exposure to this market <xref rid="bib0005" ref-type="bibr">[1]</xref>. On January 7, a novel coronavirus, originally abbreviated as 2019-nCoV by WHO, was identified from the throat swab sample of a patient <xref rid="bib0010" ref-type="bibr">[2]</xref>. This pathogen was later renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group <xref rid="bib0015" ref-type="bibr">[3]</xref> and the disease was named coronavirus disease 2019 (COVID-19) by the WHO. As of January 30, 7736 confirmed and 12,167 suspected cases had been reported in China and 82 confirmed cases had been detected in 18 other countries <xref rid="bib0020" ref-type="bibr">[4]</xref>. In the same day, WHO declared the SARS-CoV-2 outbreak as a Public Health Emergency of International Concern (PHEIC) <xref rid="bib0020" ref-type="bibr">[4]</xref>.</p><p id="par0010">According to the National Health Commission of China, the mortality rate among confirmed cased in China was 2.1% as of February 4 <xref rid="bib0025" ref-type="bibr">[5]</xref> and the mortality rate was 0.2% among cases outside China <xref rid="bib0030" ref-type="bibr">[6]</xref>. Among patients admitted to hospitals, the mortality rate ranged between 11% and 15% <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>. COVID-19 is moderately infectious with a relatively high mortality rate, but the information available in public reports and published literature is rapidly increasing. The aim of this review is to summarize the current understanding of COVID-19 including causative agent, pathogenesis of the disease, diagnosis and treatment of the cases, as well as control and prevention strategies.</p></sec><sec id="sec0010"><title>Discussion</title><sec id="sec0015"><title>The virus: classification and origin</title><p id="par0015">SARS-CoV-2 is a member of the family <italic>Coronaviridae</italic> and order <italic>Nidovirales.</italic> The family consists of two subfamilies, <italic>Coronavirinae</italic> and <italic>Torovirinae</italic> and members of the subfamily <italic>Coronavirinae</italic> are subdivided into four genera: (a) Alphacoronavirus contains the human coronavirus (HCoV)-229E and HCoV-NL63; (b) Betacoronavirus includes HCoV-OC43, Severe Acute Respiratory Syndrome human coronavirus (SARS-HCoV), HCoV-HKU1, and Middle Eastern respiratory syndrome coronavirus (MERS-CoV); (c) Gammacoronavirus includes viruses of whales and birds and; (d) Deltacoronavirus includes viruses isolated from pigs and birds <xref rid="bib0045" ref-type="bibr">[9]</xref>. SARS-CoV-2 belongs to Betacoronavirus together with two highly pathogenic viruses, SARS-CoV and MERS-CoV. SARS-CoV-2 is an enveloped and positive-sense single-stranded RNA (+ssRNA) virus <xref rid="bib0080" ref-type="bibr">[16]</xref>.</p><p id="par0020">SARS-CoV-2 is considered a novel human-infecting Betacoronavirus <xref rid="bib0050" ref-type="bibr">[10]</xref>. Phylogenetic analysis of the SARS-CoV-2 genome indicates that the virus is closely related (with 88% identity) to two bat-derived SARS-like coronaviruses collected in 2018 in eastern China (bat-SL-CoVZC45 and bat-SL-CoVZXC21) and genetically distinct from SARS-CoV (with about 79% similarity) and MERS-CoV <xref rid="bib0050" ref-type="bibr">[10]</xref>. Using the genome sequences of SARS-CoV-2, RaTG13, and SARS-CoV <xref rid="bib0055" ref-type="bibr">[11]</xref>, a further study found that the virus is more related to BatCoV RaTG13, a bat coronavirus that was previously detected in <italic>Rhinolophus affinis</italic> from Yunnan Province, with 96.2% overall genome sequence identity <xref rid="bib0055" ref-type="bibr">[11]</xref>. A study found that no evidence of recombination events detected in the genome of SARS-CoV-2 from other viruses originating from bats such as BatCoV RaTG13, SARS-CoV and SARSr-CoVs <xref rid="bib0055" ref-type="bibr">[11]</xref>. Altogether, these findings suggest that bats might be the original host of this virus <xref rid="bib0050" ref-type="bibr">[10]</xref>, <xref rid="bib0055" ref-type="bibr">[11]</xref>.</p><p id="par0025">However, a study is needed to elucidate whether any intermediate hosts have facilitated the transmission of the virus to humans. Bats are unlikely to be the animal that is directly responsible for transmission of the virus to humans for several reasons <xref rid="bib0050" ref-type="bibr">[10]</xref>: (1) there were various non-aquatic animals (including mammals) available for purchase in Huanan Seafood Wholesale Market but no bats were sold or found; (2) SARS-CoV-2 and its close relatives, bat-SL-CoVZC45 and bat-SL-CoVZXC21, have a relatively long branch (sequence identity of less than 90%), suggesting those viruses are not direct ancestors of SARS-CoV-2; and (3) in other coronaviruses where bat is the natural reservoir such as SARS-CoV and MERS-CoV, other animals have acted as the intermediate host (civets and possibly camels, respectively). Nevertheless, bats do not always need an intermediary host to transmit viruses to humans. For example, Nipah virus in Bangladesh is transmitted through bats shedding into raw date palm sap <xref rid="bib0060" ref-type="bibr">[12]</xref>.</p></sec><sec id="sec0020"><title>Transmission</title><p id="par0030">The role of the Huanan Seafood Wholesale Market in propagating disease is unclear. Many initial COVID-19 cases were linked to this market suggesting that SARS-CoV-2 was transmitted from animals to humans <xref rid="bib0065" ref-type="bibr">[13]</xref>. However, a genomic study has provided evidence that the virus was introduced from another, yet unknown location, into the market where it spread more rapidly, although human-to-human transmission may have occurred earlier <xref rid="bib0070" ref-type="bibr">[14]</xref>. Clusters of infected family members and medical workers have confirmed the presence of person-to-person transmission <xref rid="bib0075" ref-type="bibr">[15]</xref>. After January 1, less than 10% of patients had market exposure and more than 70% patients had no exposure to the market <xref rid="bib0065" ref-type="bibr">[13]</xref>. Person-to-person transmission is thought to occur among close contacts mainly via respiratory droplets produced when an infected person coughs or sneezes. Fomites may be a large source of transmission, as SARS-CoV has been found to persist on surfaces up to 96&#x000a0;h <xref rid="bib0080" ref-type="bibr">[16]</xref> and other coronaviruses for up to 9 days <xref rid="bib0085" ref-type="bibr">[17]</xref>.</p><p id="par0035">Whether or not there is asymptomatic transmission of disease is controversial. One initial study published on January 30 reported asymptomatic transmission <xref rid="bib0090" ref-type="bibr">[18]</xref>, but later it was found that the researchers had not directly interviewed the patient, who did in fact have symptoms prior to transmitting disease <xref rid="bib0095" ref-type="bibr">[19]</xref>. A more recent study published on February 21 also purported asymptomatic transmission <xref rid="bib0100" ref-type="bibr">[20]</xref>, but any such study could be limited by errors in self-reported symptoms or contact with other cases and fomites.</p><p id="par0040">Findings about disease characteristics are rapidly changing and subject to selection bias. A study indicated the mean incubation period was 5.2 days (95% confidence interval [95%CI]: 4.1&#x02013;7.0) <xref rid="bib0065" ref-type="bibr">[13]</xref>. The incubation period has been found to be as long as 19 or 24 days <xref rid="bib0105" ref-type="bibr">[21]</xref>, <xref rid="bib0110" ref-type="bibr">[22]</xref>, although case definitions typically rely on a 14 day window <xref rid="bib0115" ref-type="bibr">[23]</xref>.</p><p id="par0045">The basic reproductive number (<italic>R</italic>
<sub>0</sub>) has been estimated with varying results and interpretations. <italic>R</italic>
<sub>0</sub> measures the average number of infections that could result from one infected individual in a fully susceptible population <xref rid="bib0120" ref-type="bibr">[24]</xref>. Studies from previous outbreaks found <italic>R</italic>
<sub>0</sub> to be 2.7 for SARS <xref rid="bib0125" ref-type="bibr">[25]</xref> and 2.4 for 2009 pandemic H1N1 influenza <xref rid="bib0130" ref-type="bibr">[26]</xref>. One study estimated that that basic reproductive number (<italic>R</italic>
<sub>0</sub>) was 2.2 (95% CI: 1.4&#x02013;3.9) <xref rid="bib0065" ref-type="bibr">[13]</xref>. However, later in a further analysis of 12 available studies found that <italic>R</italic>
<sub>0</sub> was 3.28 <xref rid="bib0135" ref-type="bibr">[27]</xref>. Because <italic>R</italic>
<sub>0</sub> represents an average value it is also important to consider the role of super spreaders, who may be hugely responsible for outbreaks within large clusters but who would not largely influence the value of <italic>R</italic>
<sub>0</sub>
<xref rid="bib0140" ref-type="bibr">[28]</xref>. During the acute phase of an outbreak or prepandemic, <italic>R</italic>
<sub>0</sub> may be unstable <xref rid="bib0120" ref-type="bibr">[24]</xref>.</p><p id="par0050">In pregnancy, a study of nine pregnancy women who developed COVID-19 in late pregnancy suggested COVID-19 did not lead to substantially worse symptoms than in nonpregnant persons and there is no evidence for intrauterine infection caused by vertical transmission <xref rid="bib0145" ref-type="bibr">[29]</xref>.</p><p id="par0055">In hospital setting, a study involving 138 COVID-19 suggested that hospital-associated transmission of SARS-CoV-2 occurred in 41% of patients <xref rid="bib0150" ref-type="bibr">[30]</xref>. Moreover, another study on 425 patients found that the proportion of cases in health care workers gradually increased by time <xref rid="bib0065" ref-type="bibr">[13]</xref>. These cases likely reflect exposure to a higher concentration of virus from sustained contact in close quarters.</p><p id="par0060">Outside China, as of February 12, 2020, there were 441 confirmed COVID-19 cases reported in 24 countries <xref rid="bib0030" ref-type="bibr">[6]</xref> of which the first imported case was reported in Thailand on January 13, 2020 <xref rid="bib0030" ref-type="bibr">[6]</xref>, <xref rid="bib0155" ref-type="bibr">[31]</xref>. Among those countries, 11 countries have reported local transmission with the highest number of cases reported in Singapore with 47 confirmed cases <xref rid="bib0030" ref-type="bibr">[6]</xref>.</p></sec><sec id="sec0025"><title>Risk factors</title><p id="par0065">The incidence of SARS-CoV-2 infection is seen most often in adult male patients with the median age of the patients was between 34 and 59 years <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0160" ref-type="bibr">[32]</xref>. SARS-CoV-2 is also more likely to infect people with chronic comorbidities such as cardiovascular and cerebrovascular diseases and diabetes <xref rid="bib0040" ref-type="bibr">[8]</xref>. The highest proportion of severe cases occurs in adults &#x02265;60 years of age, and in those with certain underlying conditions, such as cardiovascular and cerebrovascular diseases and diabetes <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>. Severe manifestations maybe also associated with coinfections of bacteria and fungi <xref rid="bib0040" ref-type="bibr">[8]</xref>.</p><p id="par0070">Fewer COVID-19 cases have been reported in children less than 15 years <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0160" ref-type="bibr">[32]</xref>. In a study of 425 COVID-19 patients in Wuhan, published on January 29, there were no cases in children under 15 years of age <xref rid="bib0065" ref-type="bibr">[13]</xref>, <xref rid="bib0165" ref-type="bibr">[33]</xref>. Nevertheless, 28 paediatric patients have been reported by January 2020 <xref rid="bib0170" ref-type="bibr">[34]</xref>. The clinical features of infected paediatric patients vary, but most have had mild symptoms with no fever or pneumonia, and have a good prognosis <xref rid="bib0170" ref-type="bibr">[34]</xref>. Another study found that although a child had radiological ground-glass lung opacities, the patient was asymptomatic <xref rid="bib0175" ref-type="bibr">[35]</xref>. In summary, children might be less likely to be infected or, if infected, present milder manifestations than adults; therefore, it is possible that their parents will not seek out treatment leading to underestimates of COVID-19 incidence in this age group.</p></sec><sec id="sec0030"><title>Pathogenesis and immune response</title><p id="par0075">Like most other members of the coronavirus family, <italic>Betacoronavirus</italic> exhibit high species specificity, but subtle genetic changes can significantly alter their tissue tropism, host range, and pathogenicity. A striking example of the adaptability of these viruses is the emergence of deadly zoonotic diseases in human history caused by SARS-CoV <xref rid="bib0180" ref-type="bibr">[36]</xref> and MERS-CoV <xref rid="bib0185" ref-type="bibr">[37]</xref>. In both viruses, bats served as the natural reservoir and humans were the terminal host, with the palm civet and dromedary camel the intermediary host for SARS-CoV and MERS-CoV, respectively <xref rid="bib0190" ref-type="bibr">[38]</xref>, <xref rid="bib0195" ref-type="bibr">[39]</xref>. Intermediate hosts clearly play a critical role in cross species transmission as they can facilitate increased contact between a virus and a new host and enable further adaptation necessary for an effective replication in the new host <xref rid="bib0200" ref-type="bibr">[40]</xref>. Because of the pandemic potential of SARS-CoV-2, careful surveillance is immensely important to monitor its future host adaptation, viral evolution, infectivity, transmissibility, and pathogenicity.</p><p id="par0080">The host range of a virus is governed by multiple molecular interactions, including receptor interaction. The envelope spike (S) protein receptor binding domain of SARS-CoV-2 was shown structurally similar to that of SARS-CoV, despite amino acid variation at some key residues <xref rid="bib0050" ref-type="bibr">[10]</xref>. Further extensive structural analysis strongly suggests that SARS-CoV-2 may use host receptor angiotensin-converting enzyme 2 (ACE2) to enter the cells <xref rid="bib0205" ref-type="bibr">[41]</xref>, the same receptor facilitating SARS-CoV to infect the airway epithelium and alveolar type 2 (AT2) pneumocytes, pulmonary cells that synthesize pulmonary surfactant <xref rid="bib0210" ref-type="bibr">[42]</xref>. In general, the spike protein of coronavirus is divided into the S1 and S2 domain, in which S1 is responsible for receptor binding and S2 domain is responsible for cell membrane fusion <xref rid="bib0050" ref-type="bibr">[10]</xref>. The S1 domain of SARS-CoV and SARS-CoV-2 share around 50 conserved amino acids, whereas most of the bat-derived viruses showed more variation <xref rid="bib0050" ref-type="bibr">[10]</xref>. In addition, identification of several key residues (Gln493 and Asn501) that govern the binding of SARS-CoV-2 receptor binding domain with ACE2 further support that SARS-CoV-2 has acquired capacity for person-to-person transmission <xref rid="bib0205" ref-type="bibr">[41]</xref>. Although, the spike protein sequence of receptor binding SARS-CoV-2 is more similar to that of SARS-CoV, at the whole genome level SARS-CoV-2 is more closely related to bat-SL-CoVZC45 and bat-SL-CoVZXC21 <xref rid="bib0050" ref-type="bibr">[10]</xref>.</p><p id="par0085">However, receptor recognition is not the only determinant of species specificity. Immediately after binding to their receptive receptor, SARS-CoV-2 enters host cells where they encounter the innate immune response. In order to productively infect the new host, SARS-CoV-2 must be able to inhibit or evade host innate immune signalling. However, it is largely unknown how SARS-CoV-2 manages to evade immune response and drive pathogenesis. Given that COVID-19 and SARS have similar clinical features <xref rid="bib0035" ref-type="bibr">[7]</xref>, SARS-CoV-2 may have a similar pathogenesis mechanism as SARS-CoV. In response to SARS-CoV infections, the type I interferon (IFN) system induces the expression of IFN-stimulated genes (ISGs) to inhibit viral replication. To overcome this antiviral activity, SARS-CoV encodes at least 8 viral antagonists that modulate induction of IFN and cytokines and evade ISG effector function <xref rid="bib0215" ref-type="bibr">[43]</xref>.</p><p id="par0090">The host immune system response to viral infection by mediating inflammation and cellular antiviral activity is critical to inhibit viral replication and dissemination. However, excessive immune responses together with lytic effects of the virus on host cells will result in pathogenesis. Studies have shown patients suffering from severe pneumonia, with fever and dry cough as common symptoms at onset of illness <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>. Some patients progressed rapidly with Acute Respiratory Stress Syndrome (ARDS) and septic shock, which was eventually followed by multiple organ failure and about 10% of patients have died <xref rid="bib0040" ref-type="bibr">[8]</xref>. ARDS progression and extensive lung damage in COVID-19 are further indications that ACE2 might be a route of entry for the SARS-CoV-2 as ACE2 is known abundantly present on ciliated cells of the airway epithelium and alveolar type II (cells (pulmonary cells that synthesize pulmonary surfactant) in humans <xref rid="bib0220" ref-type="bibr">[44]</xref>.</p><p id="par0095">Patients with SARS and COVID-19 have similar patterns of inflammatory damage. In serum from patients diagnosed with SARS, there is increased levels of proinflammatory cytokines (e.g. interleukin (IL)-1, IL6, IL12, interferon gamma (IFN&#x003b3;), IFN-&#x003b3;-induced protein 10 (IP10), macrophage inflammatory proteins 1A (MIP1A) and monocyte chemoattractant protein-1 (MCP1)), which are associated with pulmonary inflammation and severe lung damage <xref rid="bib0225" ref-type="bibr">[45]</xref>. Likewise, patients infected with SARS-CoV-2 are reported to have higher plasma levels of proinflammatory cytokines including IL1&#x003b2;, IL-2, IL7, TNF-&#x003b1;, GSCF, MCP1 than healthy adults <xref rid="bib0035" ref-type="bibr">[7]</xref>. Importantly, patients in the intensive care unit (ICU) have a significantly higher level of GSCF, IP10, MCP1, and TNF-&#x003b1; than those non-ICU patients, suggesting that a cytokine storm might be an underlying cause of disease severity <xref rid="bib0035" ref-type="bibr">[7]</xref>. Unexpectedly, anti-inflammatory cytokines such as IL10 and IL4 were also increased in those patients <xref rid="bib0035" ref-type="bibr">[7]</xref>, which was uncommon phenomenon for an acute phase viral infection. Another interesting finding, as explained before, was that SARS-CoV-2 has shown to preferentially infect older adult males with rare cases reported in children <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>. The same trend was observed in primate models of SARS-CoV where the virus was found more likely to infect aged <italic>Cynomolgus macaque</italic> than young adults <xref rid="bib0230" ref-type="bibr">[46]</xref>. Further studies are necessary to identify the virulence factors and the host genes of SARS-CoV-2 that allows the virus to cross the species-specific barrier and cause lethal disease in humans.</p></sec><sec id="sec0035"><title>Clinical manifestations</title><p id="par0100">Clinical manifestations of 2019-nCoV infection have similarities with SARS-CoV where the most common symptoms include fever, dry cough, dyspnoea, chest pain, fatigue and myalgia <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0235" ref-type="bibr">[47]</xref>. Less common symptoms include headache, dizziness, abdominal pain, diarrhoea, nausea, and vomiting <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>. Based on the report of the first 425 confirmed cases in Wuhan, the common symptoms include fever, dry cough, myalgia and fatigue with less common are sputum production, headache, haemoptysis, abdominal pain, and diarrhoea <xref rid="bib0065" ref-type="bibr">[13]</xref>. Approximately 75% patients had bilateral pneumonia <xref rid="bib0040" ref-type="bibr">[8]</xref>. Different from SARS-CoV and MERS-CoV infections, however, is that very few COVID-19 patients show prominent upper respiratory tract signs and symptoms such as rhinorrhoea, sneezing, or sore throat, suggesting that the virus might have greater preference for infecting the lower respiratory tract <xref rid="bib0035" ref-type="bibr">[7]</xref>. Pregnant and non-pregnant women have similar characteristics <xref rid="bib0240" ref-type="bibr">[48]</xref>. The common clinical presentation of 2019-nCoV infection are presented in <xref rid="tbl0005" ref-type="table">Table 1</xref>
.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Clinical symptoms of patients with 2019-nCoV infection.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Chen et al. <xref rid="bib0040" ref-type="bibr">[8]</xref></th><th align="left">Huang et al. <xref rid="bib0035" ref-type="bibr">[7]</xref></th><th align="left">Chung et al. <xref rid="bib0245" ref-type="bibr">[49]</xref></th></tr></thead><tbody><tr><td align="left">Patient count</td><td align="left">99</td><td align="left">41</td><td align="left">21</td></tr><tr><td align="left">Age (mean, year)</td><td align="left">55.5</td><td align="left">49</td><td align="left">51</td></tr><tr><td align="left">Fever</td><td align="left">83%</td><td align="left">98%</td><td align="left">67%</td></tr><tr><td align="left">Cough</td><td align="left">81%</td><td align="left">76%</td><td align="left">43%</td></tr><tr><td align="left">Shortness of breath</td><td align="left">31%</td><td align="left">55%</td><td align="left">&#x02013;</td></tr><tr><td align="left">Myalgia</td><td align="left">11%</td><td align="left">44%</td><td align="left">3%</td></tr><tr><td align="left">Haemoptysis</td><td align="left">&#x02013;</td><td align="left">5%</td><td align="left">&#x02013;</td></tr><tr><td align="left">Sputum production</td><td align="left">&#x02013;</td><td align="left">28%</td><td align="left">&#x02013;</td></tr><tr><td align="left">Confusion</td><td align="left">9%</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Sore throat</td><td align="left">5%</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Rhinorrhoea</td><td align="left">4%</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Chest pain</td><td align="left">2%</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Diarrhoea</td><td align="left">2%</td><td align="left">1%</td><td align="left">&#x02013;</td></tr></tbody></table></table-wrap></p><p id="par0105">Severe complications such as hypoxaemia, acute ARDS, arrythmia, shock, acute cardiac injury, and acute kidney injury have been reported among COVID-19 patients <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>. A study among 99 patients found that approximately 17% patients developed ARDS and, among them, 11% died of multiple organ failure <xref rid="bib0040" ref-type="bibr">[8]</xref>. The median duration from first symptoms to ARDS was 8 days <xref rid="bib0150" ref-type="bibr">[30]</xref>.</p></sec><sec id="sec0040"><title>Diagnosis</title><p id="par0110">Efforts to control spread of COVID-19, institute quarantine and isolation measures, and appropriately clinically manage patients all require useful screening and diagnostic tools. While SARS-CoV-2 is spreading, other respiratory infections may be more common in a local community. The WHO has released a guideline on case surveillance of COVID-19 on January 31, 2020 <xref rid="bib0115" ref-type="bibr">[23]</xref>. For a person who meets certain criteria, WHO recommends to first screen for more common causes of respiratory illness given the season and location. If a negative result is found, the sample should be sent to referral laboratory for SARS-CoV-2 detection.</p><p id="par0115">Case definitions can vary by country and will evolve over time as the epidemiological circumstances change in a given location. In China, a confirmed case from January 15, 2020 required an epidemiological linkage to Wuhan within 2 weeks and clinical features such as fever, pneumonia, and low white blood cell count. On January 18, 2020 the epidemiological criterion was expanded to include contact with anyone who had been in Wuhan in the past 2 weeks <xref rid="bib0250" ref-type="bibr">[50]</xref>. Later, the case definitions removed the epidemiological linkage.</p><p id="par0120">The WHO has put forward case definitions <xref rid="bib0115" ref-type="bibr">[23]</xref>. Suspected cases of COVID-19 are persons (a) with severe acute respiratory infections (history of fever and cough requiring admission to hospital) <italic>and</italic> with no other aetiology that fully explains the clinical presentation <italic>and</italic> a history of travel to or residence in China during the 14 days prior to symptom onset; or (b) a patient with any acute respiratory illness <italic>and</italic> at least one of the following during the 14 days prior to symptom onset: contact with a confirmed or probable case of SARS-CoV-2 infection <italic>or</italic> worked in or attended a health care facility where patients with confirmed or probable SARS-CoV-2 acute respiratory disease patients were being treated. Probable cases are those for whom testing for SARS-CoV-2 is inconclusive or who test positive using a pan-coronavirus assay and without laboratory evidence of other respiratory pathogens. A confirmed case is one with a laboratory confirmation of SARS-CoV-2 infection, irrespective of clinical signs and symptoms.</p><p id="par0125">For patients who meet diagnostic criteria for SARS-CoV-2 testing, the CDC recommends collection of specimens from the upper respiratory tract (nasopharyngeal and oropharyngeal swab) and, if possible, the lower respiratory tract (sputum, tracheal aspirate, or bronchoalveolar lavage) <xref rid="bib0255" ref-type="bibr">[51]</xref>. In each country, the tests are performed by laboratories designated by the government.</p></sec><sec id="sec0045"><title>Laboratory findings</title><p id="par0130">Among COVID-19 patients, common laboratory abnormalities include lymphopenia <xref rid="bib0040" ref-type="bibr">[8]</xref>, <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, prolonged prothrombin time, and elevated lactate dehydrogenase <xref rid="bib0150" ref-type="bibr">[30]</xref>. ICU-admitted patients had more laboratory abnormalities compared with non-ICU patients <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>. Some patients had elevated aspartate aminotransferase, creatine kinase, creatinine, and C-reactive protein <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0175" ref-type="bibr">[35]</xref>. Most patients have shown normal serum procalcitonin levels <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0035" ref-type="bibr">[7]</xref>.</p><p id="par0135">COVID-19 patients have high level of IL1&#x003b2;, IFN-&#x003b3;, IP10, and MCP1 <xref rid="bib0035" ref-type="bibr">[7]</xref>. ICU-admitted patients tend to have higher concentration of granulocyte-colony stimulating factor (GCSF), IP10, MCP1A, MIP1A, and TNF-&#x003b1; <xref rid="bib0035" ref-type="bibr">[7]</xref>.</p></sec><sec id="sec0050"><title>Radiology findings</title><p id="par0140">Radiology finding may vary with patients age, disease progression, immunity status, comorbidity, and initial medical intervention <xref rid="bib0260" ref-type="bibr">[52]</xref>. In a study describing 41 of the initial cases of 2019-nCoV infection, all 41 patients had pneumonia with abnormal findings on chest computed tomography (CT-scan) <xref rid="bib0035" ref-type="bibr">[7]</xref>. Abnormalities on chest CT-scan were also seen in another study of 6 cases, in which all of them showed multifocal patchy ground-glass opacities notably nearby the peripheral sections of the lungs <xref rid="bib0175" ref-type="bibr">[35]</xref>. Data from studies indicate that the typical of chest CT-scan findings are bilateral pulmonary parenchymal ground-glass and consolidative pulmonary opacities <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>, <xref rid="bib0100" ref-type="bibr">[20]</xref>, <xref rid="bib0150" ref-type="bibr">[30]</xref>, <xref rid="bib0160" ref-type="bibr">[32]</xref>, <xref rid="bib0265" ref-type="bibr">[53]</xref>. The consolidated lung lesions among patients five or more days from disease onset and those 50 years old or older compared to 4 or fewer days and those 50 years or younger, respectively <xref rid="bib0235" ref-type="bibr">[47]</xref>.</p><p id="par0145">As the disease course continue, mild to moderate progression of disease were noted in some cases which manifested by extension and increasing density of lung opacities <xref rid="bib0245" ref-type="bibr">[49]</xref>. Bilateral multiple lobular and subsegmental areas of consolidation are typical findings on chest CT-scan of ICU-admitted patients <xref rid="bib0035" ref-type="bibr">[7]</xref>. A study among 99 patients, one patient had pneumothorax in an imaging examination <xref rid="bib0040" ref-type="bibr">[8]</xref>.</p></sec><sec id="sec0055"><title>Treatments</title><p id="par0150">Similar to MERS-CoV and SARS-CoV, there is still no specific antiviral treatment for COVID-19 <xref rid="bib0270" ref-type="bibr">[54]</xref>. Isolation and supportive care including oxygen therapy, fluid management, and antibiotics treatment for secondary bacterial infections is recommended <xref rid="bib0275" ref-type="bibr">[55]</xref>. Some COVID-19 patients progressed rapidly to ARDS and septic shock, which was eventually followed by multiple organ failure <xref rid="bib0035" ref-type="bibr">[7]</xref>, <xref rid="bib0040" ref-type="bibr">[8]</xref>. Therefore, the effort on initial management of COVID-19 must be addressed to the early recognition of the suspect and contain the disease spread by immediate isolation and infection control measures <xref rid="bib0280" ref-type="bibr">[56]</xref>.</p><p id="par0155">Currently, no vaccination is available, but even if one was available, uptake might be suboptimal. A study of intention to vaccinate during the H1N1 pandemic in the United States was around 50% at the start of the pandemic in May 2009 but had decreased to 16% by January 2010 <xref rid="bib0285" ref-type="bibr">[57]</xref>.</p><p id="par0160">Neither is a treatment available. Therefore, the management of the disease has been mostly supportive referring to the disease severity which has been introduced by WHO. If sepsis is identified, empiric antibiotic should be administered based on clinical diagnosis and local epidemiology and susceptibility information. Routine glucocorticoids administration are not recommended to use unless there are another indication <xref rid="bib0290" ref-type="bibr">[58]</xref>. Clinical evidence also does not support corticosteroid treatment <xref rid="bib0295" ref-type="bibr">[59]</xref>. Use of intravenous immunoglobulin might help for severely ill patients <xref rid="bib0040" ref-type="bibr">[8]</xref>.</p><p id="par0165">Drugs are being evaluated in line with past investigations into therapeutic treatments for SARS and MERS <xref rid="bib0300" ref-type="bibr">[60]</xref>. Overall, there is not robust evidence that these antivirals can significantly improve clinical outcomes A. Antiviral drugs such as oseltamivir combined with empirical antibiotic treatment have also been used to treat COVID-19 patients <xref rid="bib0035" ref-type="bibr">[7]</xref>. Remdesivir which was developed for Ebola virus, has been used to treat imported COVID-19 cases in US <xref rid="bib0305" ref-type="bibr">[61]</xref>. A brief report of treatment combination of Lopinavir/Ritonavir, Arbidol, and Shufeng Jiedu Capsule (SFJDC), a traditional Chinese medicine, showed a clinical benefit to three of four COVID-19 patients <xref rid="bib0310" ref-type="bibr">[62]</xref>. There is an ongoing clinical trial evaluating the safety and efficacy of lopinavir-ritonavir and interferon-&#x003b1; 2b in patients with COVID-19 <xref rid="bib0275" ref-type="bibr">[55]</xref>. Ramsedivir, a broad spectrum antivirus has demonstrated in vitro and in vivo efficacy against SARS-CoV-2 and has also initiated its clinical trial <xref rid="bib0315" ref-type="bibr">[63]</xref>, <xref rid="bib0320" ref-type="bibr">[64]</xref>. In addition, other potential drugs from existing antiviral agent have also been proposed <xref rid="bib0325" ref-type="bibr">[65]</xref>, <xref rid="bib0330" ref-type="bibr">[66]</xref>.</p></sec><sec id="sec0060"><title>Control and prevention strategies</title><p id="par0170">COVID-19 is clearly a serious disease of international concern. By some estimates it has a higher reproductive number than SARS <xref rid="bib0135" ref-type="bibr">[27]</xref>, and more people have been reported to have been infected or died from it than SARS <xref rid="bib0335" ref-type="bibr">[67]</xref>. Similar to SARS-CoV and MERS-CoV, disrupting the chain of transmission is considered key to stopping the spread of disease <xref rid="bib0340" ref-type="bibr">[68]</xref>. Different strategies should be implemented in health care settings and at the local and global levels.</p><p id="par0175">Health care settings can unfortunately be an important source of viral transmission. As shown in the model for SARS, applying triage, following correct infection control measures, isolating the cases and contact tracing are key to limit the further spreading of the virus in clinics and hospitals <xref rid="bib0340" ref-type="bibr">[68]</xref>. Suspected cases presenting at healthcare facilities with symptoms of respiratory infections (e.g. runny nose, fever and cough) must wear a face mask to contain the virus and strictly adhere triage procedure. They should not be permitted to wait with other patients seeking medical care at the facilities. They should be placed in a separated, fully ventilated room and approximately 2&#x000a0;m away from other patients with convenient access to respiratory hygiene supplies <xref rid="bib0345" ref-type="bibr">[69]</xref>. In addition, if a confirmed COVID-19 case require hospitalization, they must be placed in a single patient room with negative air pressure &#x02013; a minimum of six air changes per hour. Exhausted air has to be filtered through high efficiency particulate air (HEPA) and medical personnel entering the room should wear personal protective equipment (PPE) such as gloves, gown, disposable N95, and eye protection. Once the cases are recovered and discharged, the room should be decontaminated or disinfected and personnel entering the room need to wear PPE particularly facemask, gown, eye protection <xref rid="bib0345" ref-type="bibr">[69]</xref>.</p><p id="par0180">In a community setting, isolating infected people are the primary measure to interrupt the transmission. For example, immediate actions taken by Chinese health authorities included isolating the infected people and quarantining of suspected people and their close contacts <xref rid="bib0350" ref-type="bibr">[70]</xref>. Also, as there are still conflicting assumptions regarding the animal origins of the virus (i.e. some studies linked the virus to bat <xref rid="bib0355" ref-type="bibr">[71]</xref>, <xref rid="bib0360" ref-type="bibr">[72]</xref> while others associated the virus with snake <xref rid="bib0365" ref-type="bibr">[73]</xref>), contacts with these animal fluids or tissues or consumption of wild caught animal meet should be avoided. Moreover, educating the public to recognize unusual symptoms such as chronic cough or shortness of breath is essential therefore that they could seek medical care for early detection of the virus. If large-scale community transmission occurs, mitigating social gatherings, temporary school closure, home isolation, close monitoring of symptomatic individual, provision of life supports (e.g. oxygen supply, mechanical ventilator), personal hand hygiene, and wearing personal protective equipment such as facemask should also be enforced <xref rid="bib0370" ref-type="bibr">[74]</xref>.</p><p id="par0185">In global setting, locking down Wuhan city was one of the immediate measure taken by Chinese authorities and hence had slowed the global spread of COVID-19 <xref rid="bib0370" ref-type="bibr">[74]</xref>. Air travel should be limited for the cases unless severe medical attentions are required. Setting up temperature check or scanning is mandatory at airport and border to identify the suspected cases. Continued research into the virus is critical to trace the source of the outbreak and provide evidence for future outbreak <xref rid="bib0370" ref-type="bibr">[74]</xref>.</p></sec></sec><sec id="sec0065"><title>Conclusions</title><p id="par0190">The current COVID-19 pandemic is clearly an international public health problem. There have been rapid advances in what we know about the pathogen, how it infects cells and causes disease, and clinical characteristics of disease. Due to rapid transmission, countries around the world should increase attention into disease surveillance systems and scale up country readiness and response operations including establishing rapid response teams and improving the capacity of the national laboratory system.</p></sec><sec id="sec0070"><title>Funding</title><p id="par0195">None.</p></sec><sec id="sec0075"><title>Competing interests</title><p id="par0200">The authors declare that they have no competing interests.</p></sec><sec id="sec0080"><title>Ethical approval</title><p id="par0205">Not required.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Stratton</surname><given-names>C.W.</given-names></name><name><surname>Tang</surname><given-names>Y.W.</given-names></name></person-group><article-title>Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle</article-title><source>J Med Virol</source><year>2020</year></element-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>E</surname><given-names>I.A.</given-names></name><name><surname>Madani</surname><given-names>T.A.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Kock</surname><given-names>R.</given-names></name><name><surname>Dar</surname><given-names>O.</given-names></name></person-group><article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health &#x02013; the latest 2019 novel coronavirus outbreak in Wuhan, China</article-title><source>Int J Infect Dis</source><volume>91</volume><year>2020</year><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">31953166</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A.E.A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome-related coronavirus: the species and its viruses &#x02013; a statement of the Coronavirus Study Group</article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.02.07.937862</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Burki</surname><given-names>T.K.</given-names></name></person-group><article-title>Coronavirus in China</article-title><source>Lancet Respir Med</source><year>2020</year></element-citation></ref><ref id="bib0025"><label>5</label><mixed-citation publication-type="other" id="oref0025">NHS press conference, February 4, 2020. Beijing, China. National Health Commission (NHC) of the People's Republic of China. <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/xwbd/202002/235990d202056cfcb202043f202004a202070d202007f209703b202113c202000.shtml" id="intr0005">http://www.nhc.gov.cn/xcs/xwbd/202002/235990d202056cfcb202043f202004a202070d202007f209703b202113c202000.shtml</ext-link>.</mixed-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="book" id="sbref0030"><chapter-title>WHO: coronavirus disease 2019 (COVID-19) situation report &#x02013; 23</chapter-title><year>2020</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-20200223-ncov.pdf?sfvrsn=20200241e20200219fb20200278_20200212" id="intr0010">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200212-sitrep-20200223-ncov.pdf?sfvrsn=20200241e20200219fb20200278_20200212</ext-link> [accessed 20200213 February 20202020]</comment></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name></person-group><article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="book" id="sbref0045"><person-group person-group-type="author"><name><surname>Burrell</surname><given-names>C.</given-names></name><name><surname>Howard</surname><given-names>C.</given-names></name><name><surname>Murphy</surname><given-names>F.</given-names></name></person-group><chapter-title>Fenner and White's medical virology</chapter-title><edition>5th ed.</edition><year>2016</year><publisher-name>Academic Press</publisher-name><publisher-loc>United States</publisher-loc></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>M.</given-names></name><name><surname>Luby</surname><given-names>S.</given-names></name><name><surname>Gurley</surname><given-names>E.</given-names></name><name><surname>Hossain</surname><given-names>M.</given-names></name></person-group><article-title>Transmission of human infection with Nipah virus</article-title><source>Clin Infect Dis</source><volume>49</volume><issue>11</issue><year>2009</year><fpage>1743</fpage><lpage>1748</lpage><pub-id pub-id-type="pmid">19886791</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</article-title><source>N Engl J Med</source><volume>382</volume><issue>13</issue><year>2020</year><fpage>1199</fpage><lpage>1207</lpage><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Tang</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Corlett</surname><given-names>R.</given-names></name></person-group><article-title>Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2) using whole genomic data</article-title><source>ChinaXiv</source><year>2020</year><comment>Preprint</comment></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>To</surname><given-names>K.K.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>A.</given-names></name><name><surname>Schwebke</surname><given-names>I.</given-names></name><name><surname>Kampf</surname><given-names>G.</given-names></name></person-group><article-title>How long do nosocomial pathogens persist on inanimate surfaces? A systematic review</article-title><source>BMC Infect Dis</source><volume>6</volume><year>2006</year><fpage>130</fpage><pub-id pub-id-type="pmid">16914034</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Kampf</surname><given-names>G.</given-names></name><name><surname>Todt</surname><given-names>D.</given-names></name><name><surname>Pfaender</surname><given-names>S.</given-names></name><name><surname>Steinmann</surname><given-names>E.</given-names></name></person-group><article-title>Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents</article-title><source>J Hosp Infect</source><year>2020</year></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Rothe</surname><given-names>C.</given-names></name><name><surname>Schunk</surname><given-names>M.</given-names></name><name><surname>Sothmann</surname><given-names>P.</given-names></name><name><surname>Bretzel</surname><given-names>G.</given-names></name><name><surname>Froeschl</surname><given-names>G.</given-names></name><name><surname>Wallrauch</surname><given-names>C.</given-names></name></person-group><article-title>Transmission of 2019-nCoV infection from an asymptomatic contact in Germany</article-title><source>N Engl J Med</source><year>2020</year></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="book" id="sbref0095"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K.</given-names></name></person-group><chapter-title>Study claiming new coronavirus can be transmitted by people without symptoms was flawed</chapter-title><source>Science news</source><year>2020</year></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>T.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>D.Y.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Presumed asymptomatic carrier transmission of COVID-19</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>D.K.W.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>S.M.S.</given-names></name><name><surname>Hui</surname><given-names>K.P.Y.</given-names></name><name><surname>Krishnan</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia</article-title><source>Clin Chem</source><year>2020</year></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="book" id="sbref0115"><chapter-title>Global surveillance for human infection with novel coronavirus (2019-nCoV)</chapter-title><year>2020</year><publisher-name>World Health Organization</publisher-name></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Bauch</surname><given-names>C.</given-names></name><name><surname>Oraby</surname><given-names>T.</given-names></name></person-group><article-title>Assessing the pandemic potential of MERS-CoV</article-title><source>Lancet</source><volume>382</volume><issue>9893</issue><year>2013</year><fpage>662</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">23831143</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name><surname>Riley</surname><given-names>S.</given-names></name><name><surname>Fraser</surname><given-names>C.</given-names></name><name><surname>Donnelly</surname><given-names>C.A.</given-names></name><name><surname>Ghani</surname><given-names>A.C.</given-names></name><name><surname>Abu-Raddad</surname><given-names>L.J.</given-names></name><name><surname>Hedley</surname><given-names>A.J.</given-names></name></person-group><article-title>Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions</article-title><source>Science</source><volume>300</volume><issue>5627</issue><year>2003</year><fpage>1961</fpage><lpage>1966</lpage><pub-id pub-id-type="pmid">12766206</pub-id></element-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Sugimoto</surname><given-names>J.D.</given-names></name><name><surname>Halloran</surname><given-names>M.E.</given-names></name><name><surname>Basta</surname><given-names>N.E.</given-names></name><name><surname>Chao</surname><given-names>D.L.</given-names></name><name><surname>Matrajt</surname><given-names>L.</given-names></name></person-group><article-title>The transmissibility and control of pandemic influenza A (H1N1) virus</article-title><source>Science</source><volume>326</volume><issue>5953</issue><year>2009</year><fpage>729</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">19745114</pub-id></element-citation></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gayle</surname><given-names>A.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names><suffix>JR.</suffix></name></person-group><article-title>The reproductive number of COVID-19 is higher compared to SARS coronavirus</article-title><source>J Travel Med</source><year>2020</year><pub-id pub-id-type="doi">10.1093/jtm/taaa021</pub-id></element-citation></ref><ref id="bib0140"><label>28</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Kucharski</surname><given-names>A.</given-names></name><name><surname>Althaus</surname><given-names>C.</given-names></name></person-group><article-title>The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission</article-title><source>Euro Surveill</source><volume>20</volume><issue>25</issue><year>2015</year><comment>pii:21167</comment></element-citation></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.E.A.</given-names></name></person-group><article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30360-3</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Sookaromdee</surname><given-names>P.</given-names></name><name><surname>Wiwanitkit</surname><given-names>V.</given-names></name></person-group><article-title>Imported cases of 2019-novel coronavirus (2019-nCoV) infections in Thailand: mathematical modelling of the outbreak</article-title><source>Asian Pac J Trop Med</source><volume>13</volume><issue>3</issue><year>2020</year><fpage>139</fpage><lpage>140</lpage></element-citation></ref><ref id="bib0160"><label>32</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Chang</surname></name><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Dela Cruz</surname><given-names>C.S.</given-names></name></person-group><article-title>Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Xiang</surname><given-names>R.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Shu</surname><given-names>S.</given-names></name></person-group><article-title>Detection of Covid-19 in children in early January 2020 in Wuhan, China</article-title><source>N Engl J Med</source><volume>382</volume><issue>14</issue><year>2020</year><fpage>1370</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">32163697</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>K.L.</given-names></name><name><surname>Yang</surname><given-names>Y.H.</given-names></name></person-group><article-title>Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue</article-title><source>World J Pediatr</source><year>2020</year></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.-W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.-H.</given-names></name><name><surname>To</surname><given-names>K.K.-W.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Severe acute respiratory syndrome</article-title><source>Nat Med</source><volume>10</volume><issue>12</issue><year>2004</year><fpage>S88</fpage><lpage>S97</lpage><pub-id pub-id-type="pmid">15577937</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><issue>19</issue><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>He</surname><given-names>Y.Q.</given-names></name><name><surname>Liu</surname><given-names>X.L.</given-names></name><name><surname>Zhuang</surname><given-names>Z.X.</given-names></name><name><surname>Cheung</surname><given-names>C.L.</given-names></name></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title><source>Science</source><volume>302</volume><issue>5643</issue><year>2003</year><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name><surname>Alagaili</surname><given-names>A.N.</given-names></name><name><surname>Briese</surname><given-names>T.</given-names></name><name><surname>Mishra</surname><given-names>N.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Sameroff</surname><given-names>S.C.</given-names></name><name><surname>Burbelo</surname><given-names>P.D.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia</article-title><source>mBio</source><volume>5</volume><issue>2</issue><year>2014</year><comment>e00884-00814</comment></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>G.</given-names></name><name><surname>Kitzman</surname><given-names>J.O.</given-names></name><name><surname>Rothenburg</surname><given-names>S.</given-names></name><name><surname>Shendure</surname><given-names>J.</given-names></name><name><surname>Geballe</surname><given-names>A.P.</given-names></name></person-group><article-title>Adaptive gene amplification as an intermediate step in the expansion of virus host range</article-title><source>PLoS Pathog</source><volume>10</volume><issue>3</issue><year>2014</year><fpage>e1004002</fpage><pub-id pub-id-type="pmid">24626510</pub-id></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS</article-title><source>J Virol</source><year>2020</year><comment>JVI.00127-00120</comment></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Moore</surname><given-names>M.J.</given-names></name><name><surname>Vasilieva</surname><given-names>N.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name><name><surname>Berne</surname><given-names>M.A.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title><source>Nature</source><volume>426</volume><issue>6965</issue><year>2003</year><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">14647384</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>A.L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon</article-title><source>Curr Opin Virol</source><volume>2</volume><issue>3</issue><year>2012</year><fpage>264</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">22572391</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J Pathol</source><volume>203</volume><issue>2</issue><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>C.K.</given-names></name><name><surname>Lam</surname><given-names>C.W.</given-names></name><name><surname>Wu</surname><given-names>A.K.</given-names></name><name><surname>Ip</surname><given-names>W.K.</given-names></name><name><surname>Lee</surname><given-names>N.L.</given-names></name><name><surname>Chan</surname><given-names>I.H.</given-names></name></person-group><article-title>Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome</article-title><source>Clin Exp Immunol</source><volume>136</volume><issue>1</issue><year>2004</year><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">15030519</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>S.L.</given-names></name><name><surname>de Lang</surname><given-names>A.</given-names></name><name><surname>van den Brand</surname><given-names>J.M.</given-names></name><name><surname>Leijten</surname><given-names>L.M.</given-names></name><name><surname>van</surname><given-names>I.W.F.</given-names></name><name><surname>Eijkemans</surname><given-names>M.J.</given-names></name></person-group><article-title>Exacerbated innate host response to SARS-CoV in aged non-human primates</article-title><source>PLoS Pathog</source><volume>6</volume><issue>2</issue><year>2010</year><fpage>e1000756</fpage><pub-id pub-id-type="pmid">20140198</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H.G.J.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>M.</given-names></name><name><surname>Bernheim</surname><given-names>A.</given-names></name><name><surname>Mei</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Zeng</surname><given-names>X.</given-names></name></person-group><article-title>CT imaging features of 2019 novel coronavirus (2019-nCoV)</article-title><source>Radiology</source><year>2020</year><fpage>200230</fpage></element-citation></ref><ref id="bib0250"><label>50</label><element-citation publication-type="book" id="sbref0250"><person-group person-group-type="author"><name><surname>China</surname><given-names>C.D.C.</given-names></name></person-group><chapter-title>Epidemic update and risk assessment of 2019 novel coronavirus</chapter-title><year>2020</year><publisher-name>Chinese Center for Diseases Control and Prevention</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf" id="intr0015">http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf</ext-link> [accessed 22 February 2020]</comment></element-citation></ref><ref id="bib0255"><label>51</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Jernigan</surname><given-names>D.B.</given-names></name></person-group><article-title>Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak&#x02014;United States, December 31, 2019&#x02013;February 4, 2020</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>69</volume><year>2020</year><fpage>140</fpage><pub-id pub-id-type="pmid">32027631</pub-id></element-citation></ref><ref id="bib0260"><label>52</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.H.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>Z.S.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>T.</given-names></name><name><surname>Fan</surname><given-names>Y.P.</given-names></name></person-group><article-title>A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)</article-title><source>Mil Med Res</source><volume>7</volume><issue>1</issue><year>2020</year><fpage>4</fpage><pub-id pub-id-type="pmid">32029004</pub-id></element-citation></ref><ref id="bib0265"><label>53</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Qi</surname><given-names>X.</given-names></name></person-group><article-title>CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia</article-title><source>Radiology</source><year>2020</year><fpage>200236</fpage></element-citation></ref><ref id="bib0270"><label>54</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>J.W.</given-names></name><name><surname>Tambyah</surname><given-names>P.A.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name></person-group><article-title>Emergence of a novel coronavirus causing respiratory illness from Wuhan, China</article-title><source>J Infect</source><year>2020</year></element-citation></ref><ref id="bib0275"><label>55</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name><surname>Habibzadeh</surname><given-names>P.</given-names></name><name><surname>Stoneman</surname><given-names>E.K.</given-names></name></person-group><article-title>The novel coronavirus: a bird's eye view</article-title><source>Int J Occup Environ Med</source><volume>11</volume><issue>2</issue><year>2020</year><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">32020915</pub-id></element-citation></ref><ref id="bib0280"><label>56</label><element-citation publication-type="book" id="sbref0280"><person-group person-group-type="author"><name><surname>Organization WH</surname></name></person-group><chapter-title>Global surveillance for human infection with novel coronavirus (2019-nCoV)</chapter-title><year>2020</year></element-citation></ref><ref id="bib0285"><label>57</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name><surname>Gidengil</surname><given-names>C.</given-names></name><name><surname>Parker</surname><given-names>A.</given-names></name><name><surname>Zikmund-Fisher</surname><given-names>B.</given-names></name></person-group><article-title>Trends in risk perceptions and vaccination intentions: a longitudinal study of the first year of the H1N1 pandemic</article-title><source>Am J Public Health</source><volume>102</volume><year>2012</year><fpage>672</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">22397349</pub-id></element-citation></ref><ref id="bib0290"><label>58</label><element-citation publication-type="book" id="sbref0290"><person-group person-group-type="author"><name><surname>Organization WH</surname></name></person-group><chapter-title>Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected</chapter-title><year>2020</year></element-citation></ref><ref id="bib0295"><label>59</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>C.</given-names></name><name><surname>Millar</surname><given-names>J.</given-names></name><name><surname>Baillie</surname><given-names>J.</given-names></name></person-group><article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title><source>Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>473</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">32043983</pub-id></element-citation></ref><ref id="bib0300"><label>60</label><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name><surname>Paules</surname><given-names>C.I.</given-names></name><name><surname>Marston</surname><given-names>H.D.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>Coronavirus infections &#x02013; more than just the common cold</article-title><source>JAMA</source><year>2020</year></element-citation></ref><ref id="bib0305"><label>61</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N Engl J Med</source><year>2020</year></element-citation></ref><ref id="bib0310"><label>62</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment</article-title><source>Biosci Trends</source><year>2020</year></element-citation></ref><ref id="bib0315"><label>63</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year></element-citation></ref><ref id="bib0320"><label>64</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Cronin</surname><given-names>J.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Thomas</surname><given-names>T.</given-names></name></person-group><article-title>Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci USA</source><volume>3</volume><year>2020</year><fpage>20192208</fpage></element-citation></ref><ref id="bib0325"><label>65</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.-J.</given-names></name></person-group><article-title>Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines</article-title><source>bioRxiv</source><year>2020</year><comment>2020.2001.2029.924100</comment></element-citation></ref><ref id="bib0330"><label>66</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H.</given-names></name></person-group><article-title>Drug treatment options for the 2019-new coronavirus (2019-nCoV)</article-title><source>Biosci Trends</source><year>2020</year></element-citation></ref><ref id="bib0335"><label>67</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name><surname>Mahase</surname><given-names>E.</given-names></name></person-group><article-title>Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate</article-title><source>BMJ</source><volume>368</volume><year>2020</year><fpage>m641</fpage><pub-id pub-id-type="pmid">32071063</pub-id></element-citation></ref><ref id="bib0340"><label>68</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Lau</surname><given-names>S.K.P.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Cheng</surname><given-names>V.C.C.</given-names></name><name><surname>Woo</surname><given-names>P.C.Y.</given-names></name><name><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease</article-title><source>Clin Microbiol Rev</source><volume>28</volume><issue>2</issue><year>2015</year><fpage>465</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">25810418</pub-id></element-citation></ref><ref id="bib0345"><label>69</label><element-citation publication-type="book" id="sbref0345"><person-group person-group-type="author"><name><surname>Centers for Diseases Control and Prevention</surname></name></person-group><chapter-title>Coronavirus disease 2019 (COVID-19)</chapter-title><year>2020</year></element-citation></ref><ref id="bib0350"><label>70</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><year>2020</year></element-citation></ref><ref id="bib0355"><label>71</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name><surname>Paraskevis</surname><given-names>D.</given-names></name><name><surname>Kostaki</surname><given-names>E.G.</given-names></name><name><surname>Magiorkinis</surname><given-names>G.</given-names></name><name><surname>Panayiotakopoulos</surname><given-names>G.</given-names></name><name><surname>Sourvinos</surname><given-names>G.</given-names></name><name><surname>Tsiodras</surname><given-names>S.</given-names></name></person-group><article-title>Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event</article-title><source>Infect Genet Evol</source><year>2020</year><fpage>104212</fpage><pub-id pub-id-type="pmid">32004758</pub-id></element-citation></ref><ref id="bib0360"><label>72</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name><surname>Randhawa</surname><given-names>G.S.</given-names></name><name><surname>Soltysiak</surname><given-names>M.P.M.</given-names></name><name><surname>El Roz</surname><given-names>H.</given-names></name><name><surname>De Souza</surname><given-names>C.P.</given-names></name><name><surname>Hill</surname><given-names>K.A.</given-names></name><name><surname>Kari</surname><given-names>L.</given-names></name></person-group><article-title>Machine learning analysis of genomic signatures provides evidence of associations between Wuhan 2019-nCoV and bat betacoronaviruses</article-title><source>BioRxiv</source><year>2020</year></element-citation></ref><ref id="bib0365"><label>73</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zai</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human</article-title><source>J Med Virol</source><year>2020</year></element-citation></ref><ref id="bib0370"><label>74</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name><surname>Heymann</surname><given-names>D.L.</given-names></name><name><surname>Shindo</surname><given-names>N.</given-names></name></person-group><article-title>COVID-19: what is next for public health?</article-title><source>Lancet</source><year>2020</year></element-citation></ref></ref-list></back></article>